BARCELONA, Spain and DÜSSELDORF, Germany, July 24, 2026 -- Minoryx Therapeutics and Neuraxpharm Group, announce that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has...
Taking Aim at Melanoma - The Scientist - Magazine of the Life Sciences
News | 04. 01. 2011
Understanding oncogenesis at the molecular level offers the prospect of tailoring treatments much more precisely for patients with advanced cases of this deadliest of skin cancers.
